



20 April 2022

**Clinical Trial Results; No Subjects Enrolled in UK or EU/EEA**

**EudraCT: 2018-003093-27**

To whom it may concern,

On behalf of the Sponsor, GB002, Inc., we wish to notify you that, for the clinical trial described below, although a EudraCT number was assigned and MHRA approval was granted (MHRA ref; 55555-0001-001), no subjects were enrolled in the United Kingdom or European Union.

Furthermore, this investigational medicinal product (seralutinib, also known as GB002) does not have a marketing authorization in the EU/UK and is not the subject of any ongoing MAA procedure.

Therefore, GB002, Inc. will not be submitting study results to EudraCT for the study described below.

| <b>EudraCT number</b> | <b>Sponsor code</b> | <b>Title</b>  |
|-----------------------|---------------------|---|
| 2018-003093-27        | GB002-1101          | A Phase 1b, Randomized, Subject- And Investigator Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled Gb002 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH) |

Please contact me if you require any additional information.

Yours sincerely,

DocuSigned by:

Conor O'Donovan



Signer Name: Conor O'Donovan  
Signing Reason: I approve this document  
Signing Time: 28-Apr-22 | 3:26 AM PDT

Conor O'Donovan

B6703E7BCB2D4CA1B952922FE9CF3D9B  
Executive Director, Regulatory Affairs

Gossamer Bio 002 Limited, on behalf of GB002, Inc.

+353-1-526-9881

[codonovan@gossamerbio.com](mailto:codonovan@gossamerbio.com)